Thus, while VEGF expression serves as a useful prognostic marker and indicates potential responsiveness to anti-angiogenic therapies, its role in improving survival outcomes remains limited, with ongoing research exploring combination approaches to enhance its therapeutic impact in glioblastoma. This evidence concerns the gene VEGFA and glioblastoma.